Trevi is developing Nalbuphine® ER for chronic severe pruritic conditions. The two lead indications in development are prurigo nodularis and uremic pruritus.

If you are interested in participating as a Clinical Trial Site for a study in Chronic Prurigo (CPG) / Prurigo Nodularis (PN), please complete the Physician clinical trial interest form.